Literature DB >> 18832924

New advances in hematopoietic cell transplantation.

Effie W Petersdorf1, John A Hansen.   

Abstract

PURPOSE OF REVIEW: The present review highlights sentinel work published since 2006 on the definition of the transplantation barrier and the elucidation of cytokine and immune response gene variation in defining posttransplant risks. RECENT
FINDINGS: Recent work has defined the relative importance of matching for the classical human leukocyte antigen (HLA) HLA-A, HLA-B, HLA-C, DRB1, DQB1 genes, and the importance of additive effects of multilocus disparity. This work provides a new framework for donor identification and extends the use of single locus HLA-DQB1 mismatched donors without compromising the success of the transplant. New data demonstrate that permissible class I mismatches may be defined by donor-recipient mismatching at certain residues. The concept that the extended HLA haplotype carries undetected but functional variation provides an approach for mapping novel transplantation determinants, and a means to further improve the clinical results of transplantation from HLA-matched unrelated donors. Finally, the role of sequence variation in immune response and cytokine genes provides a means for assessing risks for a given transplant recipient and may aid in the planning of the transplant procedure.
SUMMARY: Optimizing the results of unrelated donor transplantation requires an understanding of risks associated with variation of HLA genes within the major histocompatibility complex, and of genes that participate in the immune response and inflammatory pathways.

Entities:  

Mesh:

Year:  2008        PMID: 18832924      PMCID: PMC3173041          DOI: 10.1097/MOH.0b013e328311891f

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  56 in total

1.  Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants.

Authors:  J Cavet; P G Middleton; M Segall; H Noreen; S M Davies; A M Dickinson
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

2.  Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain.

Authors:  G B Ferrara; A Bacigalupo; T Lamparelli; E Lanino; L Delfino; A Morabito; A M Parodi; C Pera; S Pozzi; M P Sormani; P Bruzzi; D Bordo; M Bolognesi; G Bandini; A Bontadini; M Barbanti; G Frumento
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

3.  Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation.

Authors:  H Takahashi; T Furukawa; S Hashimoto; N Suzuki; T Kuroha; F Yamazaki; K Inano; M Takahashi; Y Aizawa; T Koike
Journal:  Bone Marrow Transplant       Date:  2000-12       Impact factor: 5.483

4.  The National Marrow Donor Program. Meeting the needs of the medically underserved.

Authors:  D L Confer
Journal:  Cancer       Date:  2001-01-01       Impact factor: 6.860

5.  Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  G Socié; P Loiseau; R Tamouza; A Janin; M Busson; E Gluckman; D Charron
Journal:  Transplantation       Date:  2001-08-27       Impact factor: 4.939

6.  The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors.

Authors:  Yasuo Morishima; Takehiko Sasazuki; Hidetoshi Inoko; Takeo Juji; Tatsuya Akaza; Ken Yamamoto; Yoshihide Ishikawa; Shunichi Kato; Hiroshi Sao; Hisashi Sakamaki; Keisei Kawa; Nobuyuki Hamajima; Shigetaka Asano; Yoshihisa Kodera
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

7.  Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants.

Authors:  H Cullup; A M Dickinson; G H Jackson; P R Taylor; J Cavet; P G Middleton
Journal:  Br J Haematol       Date:  2001-06       Impact factor: 6.998

8.  High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation.

Authors:  Margaret L MacMillan; Gretchen A Radloff; William R Kiffmeyer; Todd E DeFor; Daniel J Weisdorf; Stella M Davies
Journal:  Transplantation       Date:  2003-12-27       Impact factor: 4.939

9.  Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation.

Authors:  Vanderson Rocha; Rendrik F Franco; Raphael Porcher; Henrique Bittencourt; Wilson A Silva; Aurelien Latouche; Agnes Devergie; Helene Esperou; Patricia Ribaud; Gerard Socie; Marco Antonio Zago; Eliane Gluckman
Journal:  Blood       Date:  2002-07-25       Impact factor: 22.113

10.  Gene and haplotype frequencies for the loci hLA-A, hLA-B, and hLA-DR based on over 13,000 german blood donors.

Authors:  Carlheinz R Müller; Gerhard Ehninger; Shraga F Goldmann
Journal:  Hum Immunol       Date:  2003-01       Impact factor: 2.850

View more
  4 in total

Review 1.  Allogeneic hematopoietic cell transplantation: the state of the art.

Authors:  Boglarka Gyurkocza; Andrew Rezvani; Rainer F Storb
Journal:  Expert Rev Hematol       Date:  2010-06       Impact factor: 2.929

2.  A mindfulness-based program for improving quality of life among hematopoietic stem cell transplantation survivors: feasibility and preliminary findings.

Authors:  Paul Grossman; Diana Zwahlen; Jorg P Halter; Jakob R Passweg; Claudia Steiner; Alexander Kiss
Journal:  Support Care Cancer       Date:  2014-10-10       Impact factor: 3.603

3.  Impact of genomic polymorphisms on the repertoire of human MHC class I-associated peptides.

Authors:  Diana Paola Granados; Dev Sriranganadane; Tariq Daouda; Antoine Zieger; Céline M Laumont; Olivier Caron-Lizotte; Geneviève Boucher; Marie-Pierre Hardy; Patrick Gendron; Caroline Côté; Sébastien Lemieux; Pierre Thibault; Claude Perreault
Journal:  Nat Commun       Date:  2014-04-09       Impact factor: 14.919

4.  Protocol for updating a systematic review of randomised controlled trials on the prophylactic use of intravenous immunoglobulin for patients undergoing haematopoietic stem cell transplantation.

Authors:  Juthaporn Cowan; D W Cameron; Greg Knoll; Jason Tay
Journal:  BMJ Open       Date:  2015-08-21       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.